Literature DB >> 22641171

The propylene glycol research project to illustrate the feasibility and difficulties to study toxicokinetics in neonates.

Aida Kulo1, Jan N de Hoon, Karel Allegaert.   

Abstract

This paper aims to describe our propylene glycol (PG) research project to illustrate the feasibility and the difficulties encountered to perform excipient studies in neonates. PG is frequently co-administered excipient. PG accumulation potentially results in hyperosmolarity, lactic acidosis or hepato-renal toxicity in adults, reflecting issues related to pharmacokinetics (PKs) and -dynamics (PDs). Consequently, similar observations in neonates are urgently needed. Since newborns display 'physiological' impaired hepatic and renal elimination capacity, description of PG PK in neonates is warranted. The PG PD was assessed based on indicators of renal, hepatic and metabolic (in)tolerance earlier reported in adults and relating to osmolar changes. Based on the PK and PD data collected in neonates, we suggest that there is a lower limit of PG tolerance in neonates. In addition to preliminary data on PG disposition and tolerance in neonates, we mainly focus on the limitations of the current observations and the difficulties encountered during this PG project to further illustrate the specific setting of neonatal research.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22641171     DOI: 10.1016/j.ijpharm.2012.05.014

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  12 in total

Review 1.  Pharmacokinetics in neonatal prescribing: evidence base, paradigms and the future.

Authors:  Kate O'Hara; Ian M R Wright; Jennifer J Schneider; Alison L Jones; Jennifer H Martin
Journal:  Br J Clin Pharmacol       Date:  2015-10-26       Impact factor: 4.335

Review 2.  Educational paper: formulation-related issues in pediatric clinical pharmacology.

Authors:  Catherine Tuleu; Joerg Breitkreutz
Journal:  Eur J Pediatr       Date:  2012-10-31       Impact factor: 3.183

3.  Pediatric clinical pharmacology: an introduction to a series of educational papers.

Authors:  Karel Allegaert
Journal:  Eur J Pediatr       Date:  2013-01-05       Impact factor: 3.183

4.  Toxic excipients in medications for neonates in Brazil.

Authors:  Alcidésio Souza; Djanilson Santos; Said Fonseca; Marina Medeiros; Lívia Batista; Mark Turner; Helena Coelho
Journal:  Eur J Pediatr       Date:  2014-02-06       Impact factor: 3.183

5.  Neonates need tailored drug formulations.

Authors:  Karel Allegaert
Journal:  World J Clin Pediatr       Date:  2013-02-08

6.  Substitution as a Strategy to Improve Excipient Exposure in Neonates: One Piece of the Puzzle.

Authors:  Karel Allegaert; Isabel Spriet
Journal:  Paediatr Drugs       Date:  2016-06       Impact factor: 3.022

Review 7.  Summary of the National Institute of Child Health and Human Development-best pharmaceuticals for Children Act Pediatric Formulation Initiatives Workshop-Pediatric Biopharmaceutics Classification System Working Group.

Authors:  Susan M Abdel-Rahman; Gordon L Amidon; Ajay Kaul; Viera Lukacova; Alexander A Vinks; Gregory T Knipp
Journal:  Clin Ther       Date:  2012-11       Impact factor: 3.393

Review 8.  Drug-induced acid-base disorders.

Authors:  Daniel Kitterer; Matthias Schwab; M Dominik Alscher; Niko Braun; Joerg Latus
Journal:  Pediatr Nephrol       Date:  2014-11-05       Impact factor: 3.714

9.  A retrospective and observational analysis of harmful excipients in medicines for hospitalised neonates in Latvia.

Authors:  Inese Sviestina; Dzintars Mozgis
Journal:  Eur J Hosp Pharm       Date:  2017-03-03

Review 10.  The safety evaluation of food flavouring substances: the role of metabolic studies.

Authors:  Robert L Smith; Samuel M Cohen; Shoji Fukushima; Nigel J Gooderham; Stephen S Hecht; F Peter Guengerich; Ivonne M C M Rietjens; Maria Bastaki; Christie L Harman; Margaret M McGowen; Sean V Taylor
Journal:  Toxicol Res (Camb)       Date:  2018-03-28       Impact factor: 3.524

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.